|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P = 0.022).
|
22166526 |
2010 |
|
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest an association between the XPC genotypes of the A499V, K939Q and PAT polymorphisms and urinary-bladder cancer.
|
20887739 |
2010 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52).
|
19924443 |
2010 |
|
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52).
|
19924443 |
2010 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility.
|
19924443 |
2010 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest an association between the XPC genotypes of the A499V, K939Q and PAT polymorphisms and urinary-bladder cancer.
|
20887739 |
2010 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
These analyses suggest that XPC Lys(939)Gln, PAT+/- and Ala(499)Val likely contribute to susceptibility to cancers.
|
18771913 |
2008 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated the association of two common non-synonymous polymorphisms in XPC (Ala499Val and Lys939Gln) with breast cancer risk in the Long Island Breast Cancer Study Project (LIBCSP), a population-based case-control study.
|
18053706 |
2008 |
|
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C-->T), PAT (-/+) and Lys939Gln (A-->C), with the risk of bladder cancer.
|
17052994 |
2007 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C-->T), PAT (-/+) and Lys939Gln (A-->C), with the risk of bladder cancer.
|
17052994 |
2007 |
|
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
|
15886698 |
2005 |
|
Carcinoma of bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using logistic regression adjusting for smoking, occupational and family history, neither the heterozygote nor the homozygote variants of these polymorphisms were associated with increased bladder cancer risk (adjusted odds ratio [95% confidence interval] for heterozygote 0.82 [0.63-1.07], 0.82 [0.63-1.08] and 0.83 [0.63-1.08] for PolyAT, IVS11-6 and Lys939Gln, respectively and homozygote variant, 0.98 [0.68-1.42], 0.99 [0.69-1.43] and 1.01 [0.70-1.46]).
|
15886698 |
2005 |
|
Malignant neoplasm of urinary bladder
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using logistic regression adjusting for smoking, occupational and family history, neither the heterozygote nor the homozygote variants of these polymorphisms were associated with increased bladder cancer risk (adjusted odds ratio [95% confidence interval] for heterozygote 0.82 [0.63-1.07], 0.82 [0.63-1.08] and 0.83 [0.63-1.08] for PolyAT, IVS11-6 and Lys939Gln, respectively and homozygote variant, 0.98 [0.68-1.42], 0.99 [0.69-1.43] and 1.01 [0.70-1.46]).
|
15886698 |
2005 |
|
Colorectal Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
In the second part we selected 2 common single nucleotide polymorphisms within genes involved in NER (Xeroderma pigmentosum group C (XPC) Lys939Gln, Xeroderma pigmentosum group D (XPD) Lys751Gln) to determine the relation between them and CRC risk.
|
29793654 |
2018 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A significant association between Ala499Val polymorphism and bladder cancer was observed (OR = 1.78, CI = 1.19-2.66, p = 0.005); however, Lys939Gln was unrelated (OR = 0.97, CI = 0.65-1.45, P = 0.89).
|
27246180 |
2016 |
|
Colorectal Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The relationships between XPC polymorphisms (Lys939Gln and Ala499Val) and the susceptibility to colorectal cancer (CRC) have been studied by several researchers, but the results were inconclusive.
|
26214629 |
2015 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
|
Colorectal Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
This meta-analysis suggested that both the XPC Lys939Gln and Ala499Val polymorphisms were not risk factors for increasing colorectal cancer.
|
24385304 |
2014 |
|
Colorectal Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The XPC Lys939Gln polymorphism may play an important role in CRC development among Asians and nonsmokers.
|
24947936 |
2014 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
|
Colorectal Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Overall, Lys939Gln was significantly associated with an increased overall cancer risk (Gln/Gln vs. Lys/Lys: OR = 1.16, 95% CI = 1.07 - 1.25, p < 0.001; recessive model: OR = 1.14, 95% CI = 1.06 - 1.22, p < 0.001; dominant model: OR = 1.06, 95% CI = 1.01 - 1.11, p = 0.015 and Gln vs. Lys: OR = 1.07, 95% CI = 1.03 - 1.10, p < 0.001) and further stratifications showed an increased risk for bladder, lung and colorectal cancer, Asian populations and population-based studies.
|
23400628 |
2013 |
|
Colorectal Carcinoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
In conclusion, the current data suggested that XPC Lys939Gln and XPG Asp1104His polymorphisms might contribute to the identification of patients with increased risk for CRC.
|
22213216 |
2012 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We investigated three polymorphisms of the XPC gene (PAT, Ala499Val and Lys939Gln) in 600 subjects with bladder cancer and in 609 healthy controls by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a Chinese Han population.
|
22505326 |
2012 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We examined the associations between bladder cancer and 7 polymorphisms from 5 genes involved in the maintenance of genetic stability (MMR: MLH1-93G>A; BER: XRCC1--77T>C and Arg399Gln; NER:XPC Lys939Gln and PAT +/-; DSBR:ATM G5557A and XRCC7 G6721T) in 302 incident bladder cancer cases and 311 hospital controls.
|
22927776 |
2012 |
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia.
|
21426550 |
2011 |